We are live on ! Find out more
RNA

Atrium Therapeutics
RNA

162 hedge funds and large institutions have $198M invested in Atrium Therapeutics in 2026 Q1 according to their latest regulatory filings, with 162 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

86.6% more ownership

Funds ownership: 0% → 86.6% (+87%)

94% less call options, than puts

Call options by funds: $968K | Put options by funds: $15.6M

Holders
162
Holders Change
+162
Holders Change %
–
% of All Funds
1.99%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
162
Increased
–
Reduced
–
Closed
–
Calls
$968K
Puts
$15.6M
Net Calls
-$14.6M
Net Calls Change
-$14.6M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$21.8M
2
BlackRock
BlackRock
New York
+$16.9M
3
RCM
RA Capital Management
Massachusetts
+$12.1M
4
TAL
TIG Advisors LLC
New York
+$8.54M
5
PCM
Pentwater Capital Management
Florida
+$8.47M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$20.8M +$21.8M +1,553,210 New
BlackRock
2
BlackRock
New York
$16.1M +$16.9M +1,205,291 New
RCM
3
RA Capital Management
Massachusetts
$11.6M +$12.1M +864,102 New
VCM
4
Vanguard Capital Management
Pennsylvania
$8.38M +$8.81M +626,869 New
TAL
5
TIG Advisors LLC
New York
$8.12M +$8.54M +607,552 New
PCM
6
Pentwater Capital Management
Florida
$8.06M +$8.47M +602,649 New
OCAI
7
O'Connor Alternative Investments
New York
$7.73M +$8.12M +578,011 New
SC
8
Sessa Capital
New York
$7.37M +$7.75M +551,391 New
Goldman Sachs
9
Goldman Sachs
New York
$4.68M +$4.92M +349,950 New
FCM
10
Farallon Capital Management
California
$4.67M +$4.91M +349,360 New
VPM
11
Vanguard Portfolio Management
Pennsylvania
$4.6M +$4.84M +344,369 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$4.28M +$4.49M +319,831 New
6CM
13
683 Capital Management
New York
$4.01M +$4.21M +300,000 New
BG
14
Bellevue Group
Switzerland
$3.52M +$3.7M +263,096 New
State Street
15
State Street
Massachusetts
$3.44M +$3.61M +257,086 New
WAM
16
Weiss Asset Management
Massachusetts
$3.22M +$3.38M +240,701 New
CF
17
Cantor Fitzgerald
New York
$3.15M +$3.31M +235,637 New
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$3.14M +$3.3M +235,115 New
Squarepoint
19
Squarepoint
New York
$3.09M +$3.25M +231,466 New
APCM
20
Arbiter Partners Capital Management
New York
$3.08M +$3.23M +230,000 New
Millennium Management
21
Millennium Management
New York
$2.55M +$2.68M +190,859 New
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$2.45M +$2.58M +183,580 New
SC
23
Slotnik Capital
Texas
$2.42M +$2.54M +180,945 New
AA
24
AQR Arbitrage
Connecticut
$2.4M +$2.52M +179,713 New
Two Sigma Investments
25
Two Sigma Investments
New York
$2.39M +$2.51M +178,560 New
1
2 3 4 5

RNA Hedge Fund Activity: Q1 2026 in Review

162 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Atrium Therapeutics (RNA) for Q1 2026, worth a combined $198M.

Buyers outnumbered sellers: 162 funds opened new RNA positions and 0 closed out — a net gain of 162 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $21.8M.

  • 162 institutional investors held Atrium Therapeutics (RNA) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $198M of Atrium Therapeutics stock for Q1 2026.
  • 162 funds opened new Atrium Therapeutics positions in Q1 2026 and 0 closed out, a net change of +162 holders.
  • The largest Atrium Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $21.8M added.

Based on aggregated 13F filings for Q1 2026.